The Cancer and Blood Diseases Institute at Cincinnati Children’s provides expert care for children with newly diagnosed and relapsed / refractory neuroblastoma. Our Neuroblastoma Advanced Therapies Center offers patients and families a multidisciplinary team approach that consists of medical, surgical, radiation and diagnostic care, fertility preservation and supportive services.
The directors of the Neuroblastoma Advanced Therapies Center are Brian Weiss, MD, and Daniel von Allmen, MD. Dr. Weiss and a national leader in the study of improved treatments for neuroblastoma. His research focuses on new approaches to targeting and killing neuroblastoma cells. Dr. von Allmen is a pediatric surgeon who is a leader in surgical care for neuroblastoma patients.
Dr. Weiss leads national studies on neuroblastoma therapies and is a leader in the Children's Oncology Group's (COG) neuroblastoma committee and the New Approaches to Neuroblastoma Therapy (NANT) consortium.
Through focused collaboration, the Neuroblastoma Advanced Therapies Center develops basic and clinical research into real-world improvements for the treatment of patients with neuroblastoma.
At many hospitals, patients and families must travel to different floors or even different buildings to see various specialists. Our multidisciplinary clinic within the Cancer and Blood Diseases Institute brings these specialists together, making visits more convenient and enabling the highest level of communication and coordination of care. Leading the team are oncologists and blood and marrow transplant specialists, who have extensive experience in caring for pediatric neuroblastoma patients and in conducting clinical research.
New patients undergo a comprehensive evaluation in our clinic. Our team then develops a detailed assessment and treatment recommendations. We provide referring physicians with regular updates to ensure coordinated care. Learn more about our team.
Our team includes:
Advancing Targeted Radiation Therapies
Cincinnati Children’s is a leading center for the development and clinical testing of new approaches to neuroblastoma treatment. Our physicians and researchers are involved in many national and international research studies and develop their own protocols when treating neuroblastoma in children and infants. This work provides our patients with early access to new anticancer therapies, sometimes years before they become widely available elsewhere.
Such therapies include 131I-MIBG therapy, which targets radiation directly to neuroblastoma cells while sparing healthy tissue. Cincinnati Children’s is one of just a few pediatric centers in the country to offer the technically demanding 131I-MIBG therapy, which requires special facilities for radiation safety and a collaborative approach to care across multiple divisions. Also, one of the first centers to open the CU67 trial and to treat patients with CLR 131.
In addition, Cincinnati Children’s Proton Therapy Center offers one of the most precise and advanced forms of radiation therapy available in the world today. In the hands of the expert cancer team at Cincinnati Children’s, this specialized pencil beam technology destroys cancer cells while minimizing damage to surrounding healthy tissues and organs.
The Cincinnati Children’s / UC Health Proton Therapy Center has begun the world’s first clinical trial of FLASH radiation therapy for cancer. FLASH uses radiation delivered at ultra-high speeds up to 1,000 times faster than what is used clinically today.
We also specialize in blood and marrow transplantation. Our Bone Marrow Transplantation Program has performed more than 2,200 blood and marrow transplants, making it one of the busiest programs in the country.